Is COVID going around in Poland?

COVID-19 surveillance in Poland sits inside the broader respiratory-virus framework run by NIZP PZH. SARS-CoV-2 is reported alongside influenza and RSV via sentinel and non-sentinel networks, with results feeding into ECDC's ERVISS platform. Since mass testing wound down, the useful signals are laboratory positivity among tested respiratory samples, hospital admissions for severe acute respiratory infection, and, where available, variant sampling.

Yes, but the pattern is less tightly seasonal than influenza. Poland has seen recurring autumn and winter waves, often triggered by new Omicron sublineages that partially escape earlier immunity. Summer upticks occur as well. Because NIZP PZH reports COVID-19 within the combined respiratory panel, waves are now read as shifts in positivity and hospitalisation rather than through absolute case counts.

Poland contributes SARS-CoV-2 positivity and severity indicators to ECDC's ERVISS and country profiles. This allows a direct comparison of Polish trends with those of Germany, Czechia, Slovakia, and other neighbours. Because all countries use the same reporting template, relative intensity (low, moderate, high, very high) is meaningful across borders, even if absolute numbers are not fully comparable.

For most people with vaccine- or infection-induced immunity, current variants behave like a moderate respiratory illness. Risk remains concentrated in older adults, immunocompromised patients, and people with chronic heart or lung disease. Polish public-health guidance continues to recommend seasonal booster doses for risk groups, aligned with ECDC and WHO Europe recommendations. Ongoing surveillance is what allows that risk to be managed without blanket restrictions.

NIZP PZH and ECDC use tiered activity classifications, baseline through very high, derived from historical positivity and severity ranges. These tiers describe how the current week compares with previous seasons, not how many people are infected in absolute terms. A shift from moderate to high signals meaningful additional pressure on primary care and hospitals, even when case-level data is incomplete.